Rafferty Asset Management
NUVB icon

Rafferty Asset Management’s Nuvation Bio NUVB Stock Holding History

Rafferty Asset Management’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$137K Buy
31,964
+2,143
+7% +$11.9K ﹤0.01% 1043
2025
Q4 		$267K Sell
29,821
-10,084
-25% -$62.5K ﹤0.01% 1019
2025
Q3 		$148K Buy
39,905
+11,539
+41% +$31.4K ﹤0.01% 1087
2025
Q2 		$55.3K Sell
28,366
-3,286
-10% -$6.84K ﹤0.01% 1074
2025
Q1 		$55.7K Buy
31,652
+7,325
+30% +$16.7K ﹤0.01% 1056
2024
Q4 		$64.7K Sell
24,327
-2,324
-9% -$5.98K ﹤0.01% 1136
2024
Q3 		$61K Buy
26,651
+10,480
+65% +$32K ﹤0.01% 1135
2024
Q2 		$47.2K Buy
+16,171
New +$49.3K ﹤0.01% 1167
2022
Q4 		– Sell
-14,847
Closed -$33K – 1142
2022
Q3 		$33K Buy
14,847
+1,708
+13% +$4.88K ﹤0.01% 1136
2022
Q2 		$43K Buy
+13,139
New +$57.3K ﹤0.01% 1109
2021
Q4 		– Sell
-10,021
Closed -$100K – 1322
2021
Q3 		$100K Buy
+10,021
New +$90.8K ﹤0.01% 1227

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Rafferty Asset Management's NUVB Position: Q1 2026 in Review

Rafferty Asset Management increased its Nuvation Bio (NUVB) stake by 7.2% in Q1 2026, buying an estimated $11.9K and bringing the position to 31,964 shares worth $137K. The position accounts for ﹤0.01% of the portfolio, ranked #1043.

Rafferty Asset Management first reported a position in NUVB in Q3 2021 and has held it in 11 quarters since. The position peaked at $267K in Q4 2025. 231 funds tracked by Wall St. Rank hold NUVB as of Q1 2026.

  • Rafferty Asset Management held 31,964 shares of Nuvation Bio worth $137K as of Q1 2026.
  • Rafferty Asset Management bought 2,143 Nuvation Bio shares in Q1 2026, an estimated $11.9K.
  • Nuvation Bio made up ﹤0.01% of Rafferty Asset Management's portfolio in Q1 2026, its #1043 holding.
  • Rafferty Asset Management first reported a position in Nuvation Bio in Q3 2021 and has held it in 11 quarters since.
  • Rafferty Asset Management's Nuvation Bio position peaked at $267K in Q4 2025.
  • 231 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2026.

Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.